Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells

British Journal of Pharmacology

Volumn 160, Issue 5, 2010, Pages 1144-1157

  Czyz, M ^a   Lesiak Mieczkowska, K ^a   Koprowska, K ^a   Szulawska Mroczek, A ^a   Wozniak, M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Cell cycle arrest; Cisplatin; Invasiveness; Melanoma; NF B pathway; Parthenolide; Polypharmacology

Indexed keywords

CISPLATIN; CYCLIN D1; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MATRIGEL; PARTHENOLIDE; PROTEIN BCL XL; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; SESQUITERPENE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; METASTASIS POTENTIAL; MITOCHONDRIAL MEMBRANE POTENTIAL; NEWBORN; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GENE; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MELANOMA; METABOLISM; NEOPLASM METASTASIS; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NF-KAPPA B; SESQUITERPENES;

EID: 77953208098     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00749.x     Document Type: Article

References (51)

1. Baud V, Karin M (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8 : 33 40.
2. Bedoya LM, Abad MJ, Bermejo P (2008). The role of parthenolide in intracellular signalling processes: review of current knowledge. Curr Sign Transd Ther 3 : 82 87.
3. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M (1997). Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402 : 85 90.
4. Chin L, Garraway LA, Fisher DE (2006). Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20 : 2149 2182.
5. Cory AH, Cory JG (2002). Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells. Anticancer Res 22 : 3805 3809.
6. Curry EA 3rd., Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H et al 2004). Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 22 : 299 305.
7. Czyz M, Jakubowska J, Sztiller-Sikorska M (2008). STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562. Biochem Pharmacol 75 : 1761 1773.
8. Dell'Agli M, Galli GV, Bosisio E, D'Ambrosio M (2009). Inhibition of NF-kB and metalloproteinase-9 expression and secretion by parthenolide derivatives. Bioorg Med Chem Lett 19 : 1858 1860.
9. Duechler M, Stańczyk M, Czyz M, Stepnik M (2008). Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. Cancer Chemother Pharmacol 61 : 727 737.
10. Estrada Y, Dong J, Ossowski L (2009). Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res 22 : 66 76.
11. Fonrose X, Ausseil F, Soleilhac E, Masson V, David B, Pouny I et al 2007). Parthenolide inhibits tubulin carboxypeptidase activity. Cancer Res 67 : 3371 3378.
12. Francescato HD, Costa RS, Scavone C, Coimbra TM (2007). Parthenolide reduces cisplatin-induced renal damage. Toxicology 230 : 64 75.
13. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ et al 2005). Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26 : 1856 1867.
14. García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL et al 2001). Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA-binding inhibition by sesquiterpene lactones. J Biol Chem 276 : 39713 39720.
15. Gopal YN, Arora TS, Van Dyke MW (2007). Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol 14 : 813 823.
16. Gopal YN, Chanchorn E, Van Dyke MW (2009). Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 8 : 552 562.
17. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS et al 2005). The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105 : 4163 4169.
18. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V et al 1998). Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273 : 1288 1297.
19. Huang SC, Ho CT, Lin-Shiau SY, Lin JK (2005). Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. Biochem Pharmacol 69 : 221 232.
20. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH (2009). Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 8 : 2339 2347.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2008). Cancer statistics. CA Cancer J Clin 58 : 71 96.
22. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS et al 2009). Effects of the sesquiterpene lactone parthenolide on prostate tumour-initiating cells: an integrated molecular profiling approach. Prostate 69 : 827 837.
23. Kim E, Giese A, Deppert W (2009). Wild-type p53 in cancer cells : when a guardian turns into a blackguard. Biochem Pharmacol 77 : 11 20.
24. Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG (2005). Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res 65 : 6312 6320.
25. Kishida Y, Yoshikawa H, Myoui A (2007). Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 13 : 59 67.
26. Lesiak K, Koprowska K, Zalesna I, Nejc D, Duchler M, Czyz M (2010). Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro. Melanoma Res 20 : 21 34.
27. Liu Y, Lu WL, Guo J, Du J, Li T, Wu JW et al 2008). A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 129 : 18 25.
28. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P et al 2009). Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 329 : 505 514.
29. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T et al 2004). Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279 : 23477 23485.
30. Melnikova VO, Bar-Eli M (2008). Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 7 : 997 1003.
31. Moll T, Czyz M, Holzmüller H, Hofer-Warbinek R, Wagner E, Winkler H et al 1995). Regulation of the tissue factor promoter in endothelial cells. Binding of NF kappa B-, AP-1-, and Sp1-like transcription factors. J Biol Chem 270 : 3849 3857.
32. Murphy JJ, Heptinstall S, Mitchell JR (1988). Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 2 : 189 192.
33. Nakshatri H, Rice SE, Bhat-Nakshatri P (2004). Antitumour agent parthenolide reverses resistance of breast cancer cells to tumour necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23 : 7330 7344.
34. Oka D, Nishimura K, Shiba M, Nakai Y, Arai Y, Nakayama M et al 2007). Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer 120 : 2576 2581.
35. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S et al 2000). Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19 : 4159 4169.
36. Peng HH, Liang S, Henderson AJ, Dong C (2007). Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 313 : 551 559.
37. Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D et al 2009). Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol 156 : 1054 1066.
38. Schön M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vöhringer V et al 2008). KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoural treatment. J Natl Cancer Inst 100 : 862 875.
39. Smalley KSM (2010). Understanding Melanoma signalling networks as the basis for molecular targeted therapy. J Invest Dermatol 130 : 28 37.
40. Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y et al 2005). The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 4 : 1004 1012.
41. Sztiller-Sikorska M, Jakubowska J, Wozniak M, Stasiak M, Czyz M (2009). A non-apoptotic function of caspase-3 in pharmacologically-induced differentiation of K562 cells. Br J Pharmacol 157 : 1451 1462.
42. Szulawska A, Gniazdowski M, Czyz M (2005). Sequence specificity of formaldehyde-mediated covalent binding of anthracycline derivatives to DNA. Biochem Pharmacol 69 : 7 18.
43. Szulawska A, Arkusinska J, Czyz M (2007). Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives. Biochem Pharmacol 73 : 175 184.
44. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumour progression and survival. J Clin Oncol 19 : 577 583.
45. Wang W, Adachi M, Kawamura R, Sakamoto H, Hayashi T, Ishida T et al 2006). Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 11 : 2225 2235.
46. Wen J, You KR, Lee SY, Song CH, Kim DG (2002). Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277 : 38954 38964.
47. Weng SX, Sui MH, Chen S, Wang JA, Xu G, Ma J et al 2009). Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest. J Zhejiang Univ Sci B 10 : 528 535.
48. Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A (2009). Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther 8 : 636 647.
49. Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM (2005). Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther 4 : 587 594.
50. Zhang S, Won YK, Ong CN, Shen HM (2005). Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 5 : 239 249.
51. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y (2008). NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111 : 419 427.